Compare General Mills, Inc. (GIS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Moderna, Inc. — how do they compare? General Mills, Inc. trades at $32.29 (market cap $17.43B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 4.5× General Mills, Inc.'s market cap, and General Mills, Inc. pays a 7.49% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Moderna, Inc. for 59 Days on average.
| GIS | MRNA | |
|---|---|---|
Market Cap | $17.43B | $78.65B |
Volume | 16,554,362 | 37,373,437 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $203.46 |
52-Week Low | $31.67 | $22.36 |
Typical Hold Time | 106 Days | 59 Days |
Enterprise Value | $30.61B | $74.80B |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.59, up 2.58% today, but faces fundamental challenges with negative net income margin (-4.89%) and ROE (-10.55%) for 2026. The stock shows bearish technical signals with mixed earnings performance - missing Q4 2025 estimates but beating Q2 2026. Recent CEO transition to Dana McNabb and a $3 billion cost-saving initiative aim to stabilize operations amid declining revenue trends from $19.5B (2025) to $18.3B (2026).
The stock presents a high-yield opportunity with a $0.61 dividend, but significant risks include persistent margin pressure and rising debt-to-asset ratio (45% in 2025). Analyst consensus is cautious with 61% hold ratings, though the $36 price target suggests 10% upside. Investors should weigh the dividend stability against fundamental deterioration and leadership transition execution risks.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
